Fig. 3: IT treatment with VSV-mIFNß generates a dominant anti-viral CD8 T cell response which replaces the anti-tumor T cell response.

A Treatment regimen. Following hydrodynamic injection of hMet + S45Y ß-Catenin on day 0, animals were treated with anti-PD-L1 on day 21 for 6 doses concurrently with VSV-mIFNß for 3 doses. All animals were euthanized on day 38. Livers were processed into single-cell suspensions and analyzed by the Mayo CyTOF core facility. N = 16, 4 animals per group, groups were pooled for Rphenograph tSNE analysis, 22 groups. Scatterplot and mean heat map shown. B Following initial analysis (A), 9 distinct immune populations were identified and pooled data was re-analyzed using FlowSOM tSNE analysis. ‘Exhausted CD8 T cells’ were identified by expression of CD8, Tim-3, LAG-3, CD39, and PD-1 expression, ‘B cells’ by CD38 and CD19; ‘CD4 T cells’ by CD4; ‘Memory CD4 T Cells’ by CD4, CCR7, and CD62L; ‘Memory CD8 T Cells’ by CD8, CCR7, and CD62L; ‘NK Cells’ by NK1.1; ‘NKT Cells’ by NK1.1 and CD8; and ‘Anti-viral CD8 T Cells’ by CD8, GranzB, and PD-L1. C Pooled analysis of lymphocytes within livers of tumor-free mice, first 10,000 events. D Pooled analysis of lymphocytes within livers of SB-HCC-bearing mice, first 10,000 events. E Pooled analysis of lymphocytes within livers of SB-HCC bearing mice treated with anti-PD-L1, first 10,000 events. F Pooled analysis of lymphocytes within livers of SB-HCC-bearing mice treated with anti-PD-L1 and VSV-mIFNß, first 10,000 events.